Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition July 21, 2023 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 What to Know About the Different Types of Mastectomies for Breast... March 2, 2023 After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family January 4, 2022 Load more HOT NEWS After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... The Caregiver Curve BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions Saying YES: Inspiring a Diverse Generation of Cancer Scientists
